Mayne Pharma Group Limited CEO Aaron Gray talked with Jonathan Jackson from Proactive at the Small and Mid-Cap Conference about the company’s strategy, product portfolio, and recent H1 results, highlighting its focus on women’s health and dermatology markets in the United States.

Gray explained that Mayne Pharma operates across three business units, with two generating all revenue from the US, focused on women’s health and dermatology, while a third international unit covers Australia and other global markets. He emphasized the strength of its women’s health portfolio, which includes four reproductive health products spanning contraception and menopause treatment.

He noted that these are “really best in class products,” pointing to innovations such as plant-derived estrogen therapies and combination drug-device solutions designed to improve patient outcomes and access. A key priority for the company is ensuring these treatments reach patients efficiently, with Gray stating the focus is “really about patient access.”

In dermatology, Mayne Pharma holds 31 products targeting conditions such as psoriasis and acne. Despite industry challenges around insurance reimbursement, the company has differentiated itself by maintaining profitability and delivering treatments to patients through alternative access strategies. Discussing financial performance, Gray said the company delivered $212 million in H1 revenue and generated $16.9 million in operating cash flow, describing the results as “very resilient” despite a challenging environment.

Looking ahead, Mayne Pharma is focused on expanding access strategies, strengthening its salesforce, and capitalizing on growth in the US hormone replacement therapy market. Gray highlighted strong fundamentals, including patent protection, growing market share, and “significant headroom to take more market share”

#proactiveinvestors #asx #myx #otc #maynf #MaynePharma #WomensHealth #Dermatology #PharmaNews #HealthcareInvesting #Biotech #USHealthcare #PharmaGrowth #InvestorInsights #HRT #MenopauseCare #DrugDevelopment #ASX #SmallCapStocks #HealthcareInnovation

View Comments